TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NKGen Biotech ( (NKGN) ) has shared an update.
On July 14, 2025, NKGen Biotech entered into a Stock Purchase Agreement with HekaBio K.K., selling 8 million shares and issuing warrants for an additional 8 million shares, raising $2 million. This funding will help NKGen address reporting compliance issues and listing standards, as their shares move temporarily to the OTC Expert Market due to filing delays. The company is working to regain compliance and aims to uplist to OTCQB and eventually return to Nasdaq or NYSE American. This investment also supports NKGen’s strategic efforts to introduce its NK cell therapy, troculeucel, to the Japanese market, and follows challenges faced due to the bankruptcy of its former parent company, NKMax Co., Ltd.
More about NKGen Biotech
NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics.
Average Trading Volume: 177,061
Technical Sentiment Signal: Sell
Current Market Cap: $13.53M
Learn more about NKGN stock on TipRanks’ Stock Analysis page.